Danaher (NYSE:DHR) Releases Quarterly Earnings Results

Danaher (NYSE:DHRGet Rating) posted its quarterly earnings data on Thursday. The conglomerate reported $2.76 EPS for the quarter, beating the consensus estimate of $2.66 by $0.10, MarketWatch Earnings reports. Danaher had a net margin of 21.84% and a return on equity of 18.87%. The business had revenue of $7.69 billion for the quarter, compared to analysts’ expectations of $7.53 billion. During the same period in the previous year, the firm posted $2.52 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year.

DHR traded down $0.94 during mid-day trading on Thursday, reaching $279.44. 110,822 shares of the company traded hands, compared to its average volume of 2,985,551. The company’s fifty day moving average price is $278.85 and its 200-day moving average price is $295.67. The stock has a market capitalization of $199.90 billion, a P/E ratio of 32.40, a P/E/G ratio of 1.30 and a beta of 0.78. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 0.53. Danaher has a 52-week low of $238.32 and a 52-week high of $333.96.

The business also recently announced a quarterly dividend, which will be paid on Friday, April 29th. Investors of record on Friday, March 25th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Thursday, March 24th. This represents a $1.00 annualized dividend and a yield of 0.36%. This is a boost from Danaher’s previous quarterly dividend of $0.21. Danaher’s dividend payout ratio (DPR) is currently 11.60%.

In related news, SVP Brian W. Ellis sold 5,365 shares of the firm’s stock in a transaction that occurred on Wednesday, February 2nd. The shares were sold at an average price of $293.99, for a total value of $1,577,256.35. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Joakim Weidemanis sold 20,508 shares of the business’s stock in a transaction on Monday, January 31st. The shares were sold at an average price of $285.24, for a total transaction of $5,849,701.92. The disclosure for this sale can be found here. Company insiders own 11.20% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Richwood Investment Advisors LLC bought a new position in shares of Danaher in the 4th quarter worth $58,000. Zullo Investment Group Inc. bought a new position in Danaher in the fourth quarter worth about $61,000. Bivin & Associates Inc. purchased a new stake in shares of Danaher during the fourth quarter valued at about $66,000. Penserra Capital Management LLC boosted its holdings in shares of Danaher by 385.3% in the 4th quarter. Penserra Capital Management LLC now owns 728 shares of the conglomerate’s stock valued at $239,000 after buying an additional 578 shares in the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new stake in Danaher in the fourth quarter valued at approximately $260,000. Hedge funds and other institutional investors own 82.84% of the company’s stock.

DHR has been the topic of a number of recent analyst reports. Zacks Investment Research cut Danaher from a “buy” rating to a “hold” rating and set a $295.00 target price on the stock. in a research report on Monday, January 31st. Wells Fargo & Company lowered their price objective on shares of Danaher from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Friday, January 28th. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Thursday, March 24th. Barclays lowered their price target on shares of Danaher from $355.00 to $325.00 and set an “overweight” rating for the company in a report on Thursday, January 27th. Finally, Robert W. Baird cut their price objective on Danaher from $340.00 to $334.00 in a report on Friday, January 28th. Two equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Buy” and an average price target of $333.40.

Danaher Company Profile (Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Read More

Earnings History for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.